<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
    <title>Tim Horn</title>
    <link rel="alternate" type="text/html" href="http://blogs.poz.com/tim/" />
    <link rel="self" type="application/atom+xml" href="http://blogs.poz.com/tim/atom.xml" />
    <id>tag:blogs.poz.com,2009-03-02:/tim//43</id>
    <updated>2012-05-14T22:06:36Z</updated>
    <subtitle>President and Editor-in-Chief, AIDSmeds</subtitle>
    <generator uri="http://www.sixapart.com/movabletype/">Movable Type 4.34-en</generator>

<entry>
    <title>The Real Travesty of HIV Care in the United States</title>
    <link rel="alternate" type="text/html" href="http://blogs.poz.com/tim/archives/2012/05/the_real_travesty_of.html" />
    <id>tag:blogs.poz.com,2012:/tim//43.400132</id>

    <published>2012-05-04T16:30:03Z</published>
    <updated>2012-05-14T22:06:36Z</updated>

    <summary>The national portrait of entry into and retention in HIV care has been consistently abysmal and the astounding dearth of data from well-designed studies exploring entry and retention strategies that could be used to construct well-formed recommendations is, perhaps, the final and most pressing frontier of HIV treatment advocacy in the United States. </summary>
    <author>
        <name>Tim Horn</name>
        <uri>http://blogs.poz.com/tim</uri>
    </author>
    
    <category term="adherence" label="adherence" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="care" label="care" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="casemanagement" label="case management" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="clinic" label="clinic" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="engagement" label="engagement" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="entry" label="entry" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="hiv" label="hiv" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="interventions" label="interventions" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="outreach" label="outreach" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="retention" label="retention" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="treatment" label="treatment" scheme="http://www.sixapart.com/ns/types#tag" />
    
    <content type="html" xml:lang="en" xml:base="http://blogs.poz.com/tim/">
        The national portrait of entry into and retention in HIV care has been consistently abysmal and the astounding dearth of data from well-designed studies exploring entry and retention strategies that could be used to construct well-formed recommendations is, perhaps, the final and most pressing frontier of HIV treatment advocacy in the United States. 
    </content>
</entry>

<entry>
    <title>PrEP: A Possible Approval Like No Other</title>
    <link rel="alternate" type="text/html" href="http://blogs.poz.com/tim/archives/2011/03/prep_a_pending_appro_1.html" />
    <id>tag:blogs.poz.com,2011:/tim//43.32733</id>

    <published>2011-03-29T16:50:06Z</published>
    <updated>2012-05-14T22:09:34Z</updated>

    <summary>AIDS Healthcare Foundation&apos;s campaign against the FDA approval of Truvada as PrEP is misplaced. While there are numerous lingering questions regarding the efficacy, risks and accessibility of the drug as a tool in the HIV prevention chest, the PrEP genie is already out of the bottle. Community advocacy efforts are best directed at Gilead and public health agencies to ensure safe and affordable use.  </summary>
    <author>
        <name>Tim Horn</name>
        <uri>http://blogs.poz.com/tim</uri>
    </author>
    
    <category term="ahf" label="AHF" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="aidshealthcarefoundation" label="AIDS Healthcare Foundation" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="approval" label="approval" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="fda" label="FDA" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="gilead" label="Gilead" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="hivpreventionjusticealliance" label="HIV Prevention Justice Alliance" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="iprex" label="iPrEx" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="preexposureprophylaxis" label="pre-exposure prophylaxis" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="prep" label="PrEP" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="truvada" label="Truvada" scheme="http://www.sixapart.com/ns/types#tag" />
    
    <content type="html" xml:lang="en" xml:base="http://blogs.poz.com/tim/">
        AIDS Healthcare Foundation&apos;s campaign against the FDA approval of Truvada as PrEP is misplaced. While there are numerous lingering questions regarding the efficacy, risks and accessibility of the drug as a tool in the HIV prevention chest, the PrEP genie is already out of the bottle. Community advocacy efforts are best directed at Gilead and public health agencies to ensure safe and affordable use.  
    </content>
</entry>

<entry>
    <title>2010 Treatment News in Review (Part 2)</title>
    <link rel="alternate" type="text/html" href="http://blogs.poz.com/tim/archives/2010/12/2010_treatment_news_1.html" />
    <id>tag:blogs.poz.com,2010:/tim//43.3194</id>

    <published>2010-12-30T20:37:18Z</published>
    <updated>2012-03-20T21:04:56Z</updated>

    <summary>The second of a two-part look at the top treatment news of 2010.</summary>
    <author>
        <name>Tim Horn</name>
        <uri>http://blogs.poz.com/tim</uri>
    </author>
    
    <category term="2010" label="2010" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="adap" label="ADAP" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="aging" label="aging" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="aidsdrugassistanceprograms" label="AIDS drug assistance programs" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="antiretroviraltherapy" label="antiretroviral therapy" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="bones" label="bones" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="cancer" label="cancer" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="cardiovasculardisease" label="cardiovascular disease" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="charpa" label="CHARPA" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="disability" label="disability" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="earlytreatment" label="early treatment" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="medicare" label="Medicare" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="nastad" label="NASTAD" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="socialsecurityadministration" label="social security administration" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="ssdi" label="SSDI" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="testandtreat" label="test and treat" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="waitinglists" label="waiting lists" scheme="http://www.sixapart.com/ns/types#tag" />
    
    <content type="html" xml:lang="en" xml:base="http://blogs.poz.com/tim/">
        The second of a two-part look at the top treatment news of 2010.
    </content>
</entry>

<entry>
    <title>2010 Treatment News in Review (Part 1)</title>
    <link rel="alternate" type="text/html" href="http://blogs.poz.com/tim/archives/2010/12/2010_treatment_news.html" />
    <id>tag:blogs.poz.com,2010:/tim//43.3188</id>

    <published>2010-12-27T16:31:28Z</published>
    <updated>2012-03-20T21:06:08Z</updated>

    <summary>The first of a two-part look at the top treatment news of 2010.</summary>
    <author>
        <name>Tim Horn</name>
        <uri>http://blogs.poz.com/tim</uri>
    </author>
    
    <category term="apricitabine" label="apricitabine" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="avexa" label="Avexa" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="berlinpatient" label="Berlin Patient" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="bevirimat" label="bevirimat" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="caprisa" label="CAPRISA" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="egrifta" label="Egrifta" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="emdserono" label="EMD Serono" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="healthcarereform" label="health care reform" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="iprex" label="iPrEx" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="microbicide" label="microbicide" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="myriad" label="Myriad" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="obama" label="Obama" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="pipeline" label="pipeline" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="preexposureprophylaxis" label="pre-exposure prophylaxis" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="prep" label="PrEP" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="prevention" label="prevention" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="tenofovir" label="tenofovir" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="tesamorelin" label="tesamorelin" scheme="http://www.sixapart.com/ns/types#tag" />
    
    <content type="html" xml:lang="en" xml:base="http://blogs.poz.com/tim/">
        The first of a two-part look at the top treatment news of 2010.
    </content>
</entry>

<entry>
    <title>NYC&apos;s Public Service Failure</title>
    <link rel="alternate" type="text/html" href="http://blogs.poz.com/tim/archives/2010/12/nycs_public_service.html" />
    <id>tag:blogs.poz.com,2010:/tim//43.3180</id>

    <published>2010-12-17T17:09:50Z</published>
    <updated>2010-12-17T18:04:56Z</updated>

    <summary>Scare tactics don&apos;t work, especially when the goal is to get people living with HIV who are unaware of their status tested and into care. </summary>
    <author>
        <name>Tim Horn</name>
        <uri>http://blogs.poz.com/tim</uri>
    </author>
    
    <category term="fear" label="fear" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="newyorkcitydepartmentofhealthandmentalhygiene" label="New York City Department of Health and Mental Hygiene" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="psa" label="PSA" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="scaretactics" label="scare tactics" scheme="http://www.sixapart.com/ns/types#tag" />
    
    <content type="html" xml:lang="en" xml:base="http://blogs.poz.com/tim/">
        Scare tactics don&apos;t work, especially when the goal is to get people living with HIV who are unaware of their status tested and into care. 
    </content>
</entry>

<entry>
    <title>Onward and Upward with PrEP, Cautiously</title>
    <link rel="alternate" type="text/html" href="http://blogs.poz.com/tim/archives/2010/11/onward_and_upward_wi.html" />
    <id>tag:blogs.poz.com,2010:/tim//43.3159</id>

    <published>2010-11-30T14:03:24Z</published>
    <updated>2010-11-30T19:22:13Z</updated>

    <summary>The international iPrEx study confirms that PrEP works, though not at the level researchers were initially hoping. The clinical trial, while encouraging, raises many more questions than answers. </summary>
    <author>
        <name>Tim Horn</name>
        <uri>http://blogs.poz.com/tim</uri>
    </author>
    
    <category term="emtricitabine" label="emtricitabine" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="hiv" label="HIV" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="iprex" label="iPrEx" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="preexposureprophylaxis" label="pre-exposure prophylaxis" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="prep" label="PrEP" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="projectinform" label="Project Inform" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="tenofovir" label="tenofovir" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="truvada" label="Truvada" scheme="http://www.sixapart.com/ns/types#tag" />
    
    <content type="html" xml:lang="en" xml:base="http://blogs.poz.com/tim/">
        The international iPrEx study confirms that PrEP works, though not at the level researchers were initially hoping. The clinical trial, while encouraging, raises many more questions than answers. 
    </content>
</entry>

<entry>
    <title>Fat Busting: But at What Price? </title>
    <link rel="alternate" type="text/html" href="http://blogs.poz.com/tim/archives/2010/11/fat_busting_but_at_w.html" />
    <id>tag:blogs.poz.com,2010:/tim//43.3137</id>

    <published>2010-11-12T15:30:15Z</published>
    <updated>2010-11-12T22:07:24Z</updated>

    <summary>Egrifta (tesamorelin) has been approved for the treatment of HIV-associated lipodystrophy. The question is, will a possible high price tag keep it out of the hands of those who need it? </summary>
    <author>
        <name>Tim Horn</name>
        <uri>http://blogs.poz.com/tim</uri>
    </author>
    
    <category term="abdominalfat" label="abdominal fat" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="activism" label="activism" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="atac" label="ATAC" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="cost" label="cost" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="egrifta" label="Egrifta" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="emdserono" label="EMD Serono" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="fda" label="FDA" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="lipodystrophy" label="lipodystrophy" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="lipohypertrophy" label="lipohypertrophy" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="price" label="price" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="tesamorelin" label="tesamorelin" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="theratechnologies" label="Theratechnologies" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="vat" label="VAT" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="visceraladiposetissue" label="visceral adipose tissue" scheme="http://www.sixapart.com/ns/types#tag" />
    
    <content type="html" xml:lang="en" xml:base="http://blogs.poz.com/tim/">
        Egrifta (tesamorelin) has been approved for the treatment of HIV-associated lipodystrophy. The question is, will a possible high price tag keep it out of the hands of those who need it? 
    </content>
</entry>

<entry>
    <title>The Drama is Too Damn High</title>
    <link rel="alternate" type="text/html" href="http://blogs.poz.com/tim/archives/2010/10/the_drama_is_too_dam.html" />
    <id>tag:blogs.poz.com,2010:/tim//43.3106</id>

    <published>2010-10-27T13:07:58Z</published>
    <updated>2010-10-27T18:51:16Z</updated>

    <summary>For New York voters still torn between the gubernatorial front-runners, Democratic candidate Andrew Cuomo and Republican candidate Paladino, Gay Men&apos;s Health Crisis (GMHC) has issued a clear-eyed fact sheet spelling out the candidates&apos; positions and work related to LGBT rights, HIV/AIDS prevention and care. Cuomo&apos;s and Paladino&apos;s views, past legislative actions, public statements and gubernatorial plans are outlined.</summary>
    <author>
        <name>Tim Horn</name>
        <uri>http://blogs.poz.com/tim</uri>
    </author>
    
    <category term="cuomo" label="Cuomo" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="gmhc" label="GMHC" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="gubernatorial" label="gubernatorial" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="mcmillan" label="McMillan" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="newyork" label="New York" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="paladino" label="Paladino" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="positivewomensnetwork" label="Positive Women&apos;s Network" scheme="http://www.sixapart.com/ns/types#tag" />
    
    <content type="html" xml:lang="en" xml:base="http://blogs.poz.com/tim/">
        For New York voters still torn between the gubernatorial front-runners, Democratic candidate Andrew Cuomo and Republican candidate Paladino, Gay Men&apos;s Health Crisis (GMHC) has issued a clear-eyed fact sheet spelling out the candidates&apos; positions and work related to LGBT rights, HIV/AIDS prevention and care. Cuomo&apos;s and Paladino&apos;s views, past legislative actions, public statements and gubernatorial plans are outlined.
    </content>
</entry>

<entry>
    <title>Wishing on the &quot;C&quot; Word</title>
    <link rel="alternate" type="text/html" href="http://blogs.poz.com/tim/archives/2010/10/wishing_on_the_c_wor.html" />
    <id>tag:blogs.poz.com,2010:/tim//43.3060</id>

    <published>2010-10-05T17:44:04Z</published>
    <updated>2010-10-05T19:21:45Z</updated>

    <summary>A safe and affordable cure for HIV -- whether it&apos;s a single agent or, more realistically, a combination of modalities -- won&apos;t be on the U.S. Food and Drug Administration&apos;s doorstep anytime soon. However, it&apos;s slowly coming into view on the horizon, albeit still out of focus and without any defining shape. It&apos;s no longer a mirage, but something very real indeed.</summary>
    <author>
        <name>Tim Horn</name>
        <uri>http://blogs.poz.com/tim</uri>
    </author>
    
    <category term="advocacy" label="advocacy" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="cure" label="cure" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="hiv" label="HIV" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="poz" label="POZ" scheme="http://www.sixapart.com/ns/types#tag" />
    
    <content type="html" xml:lang="en" xml:base="http://blogs.poz.com/tim/">
        A safe and affordable cure for HIV -- whether it&apos;s a single agent or, more realistically, a combination of modalities -- won&apos;t be on the U.S. Food and Drug Administration&apos;s doorstep anytime soon. However, it&apos;s slowly coming into view on the horizon, albeit still out of focus and without any defining shape. It&apos;s no longer a mirage, but something very real indeed.
    </content>
</entry>

<entry>
    <title>Social Security Disability: Will Recommended Qualification Changes Help or Hinder Access to Services?</title>
    <link rel="alternate" type="text/html" href="http://blogs.poz.com/tim/archives/2010/09/social_security_disa.html" />
    <id>tag:blogs.poz.com,2010:/tim//43.3055</id>

    <published>2010-09-30T16:43:47Z</published>
    <updated>2010-10-06T15:30:48Z</updated>

    <summary>Not everyone who has seen the recent IOM report suggesting a major overhaul of Social Security disability criteria are thrilled. Though it is clear that the IOM recommendations are only intended for new SSA disability applicants, there are concerns about how these new criteria will affect new applicants who may be relying on disability status, not only for income, but also health care and other supportive services.</summary>
    <author>
        <name>Tim Horn</name>
        <uri>http://blogs.poz.com/tim</uri>
    </author>
    
    <category term="disability" label="disability" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="housing" label="housing" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="income" label="income" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="instituteofmedicine" label="Institute of Medicine" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="insurance" label="insurance" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="iom" label="IOM" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="medicaid" label="Medicaid" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="medicare" label="Medicare" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="socialsecurityadministration" label="Social Security Administration" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="ssa" label="SSA" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="ssdi" label="SSDI" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="ssi" label="SSI" scheme="http://www.sixapart.com/ns/types#tag" />
    
    <content type="html" xml:lang="en" xml:base="http://blogs.poz.com/tim/">
        Not everyone who has seen the recent IOM report suggesting a major overhaul of Social Security disability criteria are thrilled. Though it is clear that the IOM recommendations are only intended for new SSA disability applicants, there are concerns about how these new criteria will affect new applicants who may be relying on disability status, not only for income, but also health care and other supportive services.
    </content>
</entry>

<entry>
    <title>New Jersey ADAP: No Longer a Shore Thing</title>
    <link rel="alternate" type="text/html" href="http://blogs.poz.com/tim/archives/2010/07/new_jersey_adap_no_l.html" />
    <id>tag:blogs.poz.com,2010:/tim//43.2948</id>

    <published>2010-07-13T17:17:56Z</published>
    <updated>2010-07-13T23:18:40Z</updated>

    <summary>In letters received over the weekend, the state Health Department told patients about new income guidelines for a program that enables thousands infected with HIV or diagnosed with AIDS to receive life-sustaining yet expensive antiretroviral drugs. As of Aug. 1, a patient&apos;s income cannot exceed $32,490, instead of the previous threshold of $54,150.</summary>
    <author>
        <name>Tim Horn</name>
        <uri>http://blogs.poz.com/tim</uri>
    </author>
    
    <category term="adap" label="ADAP" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="addp" label="ADDP" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="aidsdrugdistributionprogram" label="AIDS Drug Distribution Program" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="newjersey" label="New Jersey" scheme="http://www.sixapart.com/ns/types#tag" />
    
    <content type="html" xml:lang="en" xml:base="http://blogs.poz.com/tim/">
        In letters received over the weekend, the state Health Department told patients about new income guidelines for a program that enables thousands infected with HIV or diagnosed with AIDS to receive life-sustaining yet expensive antiretroviral drugs. As of Aug. 1, a patient&apos;s income cannot exceed $32,490, instead of the previous threshold of $54,150.
    </content>
</entry>

<entry>
    <title>Sleep Well, Lady</title>
    <link rel="alternate" type="text/html" href="http://blogs.poz.com/tim/archives/2010/06/sleep_well_lady.html" />
    <id>tag:blogs.poz.com,2010:/tim//43.2904</id>

    <published>2010-06-16T19:37:49Z</published>
    <updated>2010-06-17T01:53:43Z</updated>

    <summary>On the evening of June 6th, my partner, Peter, and I made the inevitable trip to our nearby veterinary hospital to put our eldest boxer, Lucy, to sleep. She was 13 years old. </summary>
    <author>
        <name>Tim Horn</name>
        <uri>http://blogs.poz.com/tim</uri>
    </author>
    
    <category term="boxers" label="boxers" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="death" label="death" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="dogs" label="dogs" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="dying" label="dying" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="euthanasia" label="euthanasia" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="living" label="living" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="lucy" label="Lucy" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="pets" label="pets" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="poz" label="POZ" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="timhorn" label="Tim Horn" scheme="http://www.sixapart.com/ns/types#tag" />
    
    <content type="html" xml:lang="en" xml:base="http://blogs.poz.com/tim/">
        On the evening of June 6th, my partner, Peter, and I made the inevitable trip to our nearby veterinary hospital to put our eldest boxer, Lucy, to sleep. She was 13 years old. 
    </content>
</entry>

<entry>
    <title>Good Lessons from Military Medicine</title>
    <link rel="alternate" type="text/html" href="http://blogs.poz.com/tim/archives/2010/05/good_lessons_from_mi.html" />
    <id>tag:blogs.poz.com,2010:/tim//43.2859</id>

    <published>2010-05-28T15:38:21Z</published>
    <updated>2010-06-17T14:10:02Z</updated>

    <summary>Free and open access to health care improves responses to antiretroviral therapy and increases disease-free survival among people living with HIV, according to a study published online May 27 by AIDS Research and Therapy. And here&apos;s the clincher: The results don&apos;t come from an analysis conducted by clinicians in the oh-so-un-American socialized medicine systems of Europe, but rather from the ever-so-American military health system of the U.S. of A.</summary>
    <author>
        <name>Tim Horn</name>
        <uri>http://blogs.poz.com/tim</uri>
    </author>
    
    <category term="antiretroviraltherapy" label="antiretroviral therapy" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="effectiveness" label="effectiveness" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="military" label="military" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="success" label="success" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="usmilitaryhivnaturalhistorystudy" label="U.S. Military HIV Natural History Study" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="vincentmarconi" label="Vincent Marconi" scheme="http://www.sixapart.com/ns/types#tag" />
    
    <content type="html" xml:lang="en" xml:base="http://blogs.poz.com/tim/">
        Free and open access to health care improves responses to antiretroviral therapy and increases disease-free survival among people living with HIV, according to a study published online May 27 by AIDS Research and Therapy. And here&apos;s the clincher: The results don&apos;t come from an analysis conducted by clinicians in the oh-so-un-American socialized medicine systems of Europe, but rather from the ever-so-American military health system of the U.S. of A.
    </content>
</entry>

<entry>
    <title>A Few Favorite DADT Myths</title>
    <link rel="alternate" type="text/html" href="http://blogs.poz.com/tim/archives/2010/05/a_few_favorite_dadt.html" />
    <id>tag:blogs.poz.com,2010:/tim//43.2858</id>

    <published>2010-05-27T17:54:51Z</published>
    <updated>2010-06-17T14:11:37Z</updated>

    <summary>As efforts to repeal the Don&apos;t Ask, Don&apos;t Tell (DADT) policy reach a political crescendo, it&apos;s fascinating to take inventory of some of the truly... errr...  &quot;creative&quot; falsehoods that have been bandied about in recent months. One in particular argues that DADT repeal would increase the risk of HIV infection among our military men and women. </summary>
    <author>
        <name>Tim Horn</name>
        <uri>http://blogs.poz.com/tim</uri>
    </author>
    
    <category term="dadt" label="DADT" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="dontaskdonttell" label="Don&apos;t ask don&apos;t tell" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="familyresearchcouncil" label="Family Research Council" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="gunnybobnewman" label="Gunny Bob Newman" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="koa" label="KOA" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="petersprigg" label="Peter Sprigg" scheme="http://www.sixapart.com/ns/types#tag" />
    
    <content type="html" xml:lang="en" xml:base="http://blogs.poz.com/tim/">
        As efforts to repeal the Don&apos;t Ask, Don&apos;t Tell (DADT) policy reach a political crescendo, it&apos;s fascinating to take inventory of some of the truly... errr...  &quot;creative&quot; falsehoods that have been bandied about in recent months. One in particular argues that DADT repeal would increase the risk of HIV infection among our military men and women. 
    </content>
</entry>

<entry>
    <title>Malawi on My Mind</title>
    <link rel="alternate" type="text/html" href="http://blogs.poz.com/tim/archives/2010/05/malawi_on_my_mind.html" />
    <id>tag:blogs.poz.com,2010:/tim//43.2846</id>

    <published>2010-05-21T14:26:40Z</published>
    <updated>2010-05-21T22:22:28Z</updated>

    <summary>If you aren&apos;t already enraged on personal and human rights levels by the sentencing of two Malawian men, Steven Monjeza and Tiwonge Chimbalanga, to 14 years of hard labor in prison after being convicted for violating &quot;the order of nature,&quot; consider the disastrous implications this tragedy of a case has on the global response to the HIV/AIDS epidemic. </summary>
    <author>
        <name>Tim Horn</name>
        <uri>http://blogs.poz.com/tim</uri>
    </author>
    
    <category term="africa" label="Africa" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="gay" label="gay" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="globalfund" label="Global Fund" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="malawi" label="Malawi" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="prevention" label="prevention" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="stevenmonjeza" label="Steven Monjeza" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="tiwongechimbalanga" label="Tiwonge Chimbalanga" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="uganda" label="Uganda" scheme="http://www.sixapart.com/ns/types#tag" />
    
    <content type="html" xml:lang="en" xml:base="http://blogs.poz.com/tim/">
        If you aren&apos;t already enraged on personal and human rights levels by the sentencing of two Malawian men, Steven Monjeza and Tiwonge Chimbalanga, to 14 years of hard labor in prison after being convicted for violating &quot;the order of nature,&quot; consider the disastrous implications this tragedy of a case has on the global response to the HIV/AIDS epidemic. 
    </content>
</entry>

</feed>

